Arca
Skip to content
Tools
Tools

NPC1L1: NPC1-like intracellular cholesterol transporter 1

Plays a major role in cholesterol homeostasis.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on NPC1L1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Ezetimibe

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        EzetimibeApprovedOrganonSmall moleculeInhibitorNiemann-Pick C1-like protein 1 inhibitor84

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Real-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary PreventionEzetimibe—Active, not recruitingXin LiNov 16, 2026
        Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular RiskEzetimibe—Not yet recruitingInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranNov 12, 2026
        A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseaseEzetimibePhase 2Active, not recruitingBeijing University of Chinese MedicineOct 30, 2026
        Feasibility of Combination Therapy With Low-dose Statin and Ezetimibe in Patients With Minimal Subclinical AtherosclerosisEzetimibePhase 4Not yet recruitingYonsei UniversityOct 13, 2026
        LDL Cholesterol Reduction Following Ezetimibe InitiationEzetimibePhase 4RecruitingUniversidade do PortoSep 24, 2026
        Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeEzetimibePhase 4RecruitingTaipei Medical University HospitalSep 17, 2026
        Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary SyndromeEzetimibePhase 4Not yet recruitingSeoul National University Bundang HospitalSep 2, 2026
        A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy AdultsEzetimibePhase 1Not yet recruitingHuons Co., Ltd.Aug 25, 2026

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Inherited lipid metabolism disorder
        0.64
        Cardiovascular disorder
        0.53
        Metabolic disease
        0.50
        Coronary artery disorder
        0.43
        Type 2 diabetes mellitus
        0.40
        Hypertensive disorder
        0.38

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2027, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9UHC9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.